$8.31 Million in Sales Expected for Alpine Immune Sciences, Inc. (NASDAQ:ALPN) This Quarter

Equities research analysts predict that Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) will announce sales of $8.31 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $4.60 million to $15.33 million. Alpine Immune Sciences reported sales of $7.19 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The company is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $65.98 million for the current fiscal year, with estimates ranging from $37.00 million to $102.00 million. For the next financial year, analysts expect that the company will post sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

A number of analysts have recently weighed in on ALPN shares. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Alpine Immune Sciences in a research report on Tuesday, May 17th. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Alpine Immune Sciences in a report on Friday, May 13th. Finally, Oppenheimer decreased their price objective on shares of Alpine Immune Sciences from $19.00 to $17.00 in a report on Monday, March 7th.

Several hedge funds and other institutional investors have recently modified their holdings of ALPN. Citigroup Inc. raised its position in Alpine Immune Sciences by 184.0% in the fourth quarter. Citigroup Inc. now owns 3,766 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,440 shares in the last quarter. Barclays PLC raised its position in Alpine Immune Sciences by 223.1% in the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 3,278 shares in the last quarter. Bank of America Corp DE raised its position in Alpine Immune Sciences by 46.7% in the fourth quarter. Bank of America Corp DE now owns 4,944 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 1,573 shares in the last quarter. Strs Ohio bought a new stake in Alpine Immune Sciences in the fourth quarter worth about $76,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in Alpine Immune Sciences in the fourth quarter worth about $83,000. Institutional investors and hedge funds own 77.00% of the company’s stock.

Shares of ALPN stock traded up $0.04 during mid-day trading on Thursday, reaching $8.34. 138,779 shares of the company were exchanged, compared to its average volume of 113,061. Alpine Immune Sciences has a fifty-two week low of $6.00 and a fifty-two week high of $14.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 2.58. The company has a market capitalization of $252.94 million, a P/E ratio of -4.69 and a beta of 1.74. The business’s 50 day simple moving average is $8.61 and its 200 day simple moving average is $9.77.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Articles

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.